Development of a Lyophilization Formulation that Preserves the Biological Activity of the Platelet-inducing Cytokine Interleukin-11 at Low Concentrations

Journal of Pharmacy and Pharmacology - Tập 52 Số 1 - Trang 19-26 - 2010
Christopher Page1, Peter J. Dawson1, David Woollacott1, Robin Thorpe1, Anthony R. Mire‐Sluis1
1Division of Immunobiology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire

Tóm tắt

AbstractRecombinant human interleukin-11 (rhIL-11) is a licensed biological therapeutic product in at least one country and is used to combat thrombocytopenia during chemotherapeutic regimens, as well as undergoing clinical trials for a range of other disorders. Following attempts to lyophilize IL-11 at low concentrations, it was clear that a significant loss of recoverable biological activity occurred.Investigation of a variety of factors, including the type of container in which the rhIL-11 was lyophilized, revealed that surface adsorption to glass was a major factor resulting in loss of activity of rhIL-11 in solution (> 40% reduction after 3 h at room temperature), in addition to losses of activity post-lyophilization. To overcome this problem, different formulations containing combinations of human serum albumin (HSA), trehalose and Tween-20 have been investigated.Two formulations were successful in entirely preserving the biological activity of rhIL-11 through lyophilization and subsequent reconstitution (potency estimates of formulated relative to original material being ≥0.97). Accelerated degradation studies, performed at intervals over a six-month period, demonstrated the stability of freeze-dried rhIL-11 using these formulations (predicted annual reduction in potency after storage at −20°C ≤1.4%).In conclusion, we have developed a working combination of excipients (0.5% HSA, 0.1% trehalose and 0.02% Tween-20 in potassium phosphate buffer (pH 7.4)) to formulate a stable rhIL-11 freeze-dried product in glass containers, with no loss in potency. These findings should facilitate development of low dose rhIL-11 products and be an indicator of caution to those using this and other material with similar physical properties, without taking appropriate precautions to avoid losses through adsorption.

Từ khóa


Tài liệu tham khảo

Du, 1994, Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment, Blood, 83, 2023, 10.1182/blood.V83.8.2023.2023

Du, 1997, Interleukin-11: review of molecular, cell biology, and clinical use, Blood, 89, 3897, 10.1182/blood.V89.11.3897

Das, 1982, Iterative weighted regression analysis of logit responses: a computer programme for analysis of bioassays and immunoassays, Comput. Methods Programs Biomed., 15, 13, 10.1016/0010-468X(82)90052-6

Hanson, 1992, Introduction to formulation of protein pharmaceuticals, Stability of Protein Pharmaceuticals. Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilisation, 209

Hermann, 1998, Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis, Arthritis Rheumatism, 41, 1388, 10.1002/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F

Kaye, 1996, Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia, Curr. Opin. Hematol., 3, 209, 10.1097/00062752-199603030-00008

Keith, 1994, IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology, Stem Cells, 12, 79

Kirkwood, 1984, Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysis, J. Biol. Stand., 12, 207, 10.1016/S0092-1157(84)80055-4

Leng, 1997, Molecules in focus: interleukin-11, Int. J. Biochem. Cell Biol., 29, 1059, 10.1016/S1357-2725(97)00017-4

Maier, 1993, Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases, J Biol. Chem., 268, 21527, 10.1016/S0021-9258(20)80573-0

Meager, 1995, RIA, IRMA, and ELISA assays for cytokines and their soluble receptors, Cytokines: A Practical Approach, 400, 10.1093/oso/9780199635672.003.0022

Mire-Sluis, 1998, WHO cytokine standardisation: facilitating the development of cytokines in research, diagnosis and as therapeutic agents, J. Immunol. Methods, 216, 103, 10.1016/S0022-1759(98)00073-8

Phillips, 1991, The use of DIN glass ampoules to freeze-dry biological materials with a low residual moisture and oxygen content, Biologicals, 19, 219, 10.1016/1045-1056(91)90038-L

Quesniaux, 1994, Interleukin 11, Leukemia Lymphoma, 14, 241, 10.3109/10428199409049674

Qui, 1996, Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats, Dig. Dis. Sci., 41, 1625, 10.1007/BF02087911

Skrabanja, 1994, Lyophilization of biotechnology products, PDA J. Pharmaceut. Sci. Technol., 48, 311

Thorpe, 1999, Bioassays for the characterisation and control of therapeutic cytokines: determination of potency, Dev. Biol. Standards, 97, 61

Timasheff, 1997, Stabilisation of protein structure by solvents, Protein Structure: A Practical Approach, 349, 10.1093/oso/9780199636198.003.0014

Wadhwa, 1995, Quantitative biological assays for individual cytokines, Cytokines: A Practical Approach, 369, 10.1093/oso/9780199635672.003.0021

Yu-Chang, 1995, Interleukin-11 (IL-11) and its receptor: biology and potential clinical applications in thrombocytopenic states, Cytokines: Interleukins and their Receptors, 321

Thông tin
Thông tin xuất bản

Journal of Pharmacy and Pharmacology

Tập 52 Số 1

19-26

Thông tin tác giả